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Abstract 
Pricing decisions and access to pharmaceuticals should be evidence based. Unfortunately, the French guidelines for technology 
assessment, in their adoption of the National Institute for Health and Clinical Excellence (NICE) reference case modeling standard ensure 
that this is not the case. Rather than requiring the submission of claims that are credible, evaluable and replicable, the Haute Autorité 
de Sante (HAS) mandates the creation of imaginary worlds to support comparative effectiveness and cost-outcome claims. The purpose 
of this commentary is to make the case that HAS should reconsider this commitment to standards for health technology assessment 
that are more appropriately seen as pseudoscience. The recommendation is that HAS should put to one side mandating lifetime cost-
per-quality adjusted life year (QALY) or life years saved claims in favor of short-term claims that can be evaluated and reported to 
health system decision makers as part of a provisional assessment of new products as well as supporting ongoing disease area and 
therapeutic class reviews.  
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Introduction 
In an Editorial in the European Journal of Health Economics in 
2013, the question was raised as to whether or not the 
National Authority for Health (HAS) should  become a French 
version of the UK National Institute for Health and Care 
Excellence (NICE) in the reference case submission standards 
required from pharmaceutical companies 1 2. More recently, 
Massetti et al in 2015 published a detailed comparison of the 
HAS and NICE guidelines pointing to both their commitment to 
a common methodology yet emphasizing the flexibility of the 
HAS guidelines in contrast the mandated reference case that is 
central to the NICE paradigm 3. The purpose of this 
commentary is to raise a question that was overlooked in both 
these papers: do the HAS guidelines meet the standards of 
normal science in a commitment to presenting competing 
claims for the cost-effectiveness of drug products that are 
credible, evaluable and replicable? 
 
Over the past 25 years, recommendations and standards for 
assessing the merits of competing health care interventions 
have focused on informing decision makers through the  
 
 
 
 
Corresponding author: Paul C Langley, PhD 
Adjunct Professor, College of Pharmacy 
University of Minnesota 
Director, Maimon Research LLC 
5061 North Apache Hills Trail, Tucson, AZ 85750 
Tel: 520-577-0436; Email: langley@maimonresearch.com  
Web:www.maimonresearch.net  
 
construction of reference case imaginary worlds 4. In the past 
nine months a number of commentaries have been published 
pointing to the lack of scientific merit in this approach to the  
economic evaluation of claims for pharmaceutical products 
and devices. These commentaries include reviews of 
technology assessment standards in the UK, Canada, Ireland, 
Australia, New Zealand and the Netherlands, together with the 
proposed European Union standards proposed under the 
EUnetHTA umbrella.5 6 7 8 9 10. These commentaries concluded 
that the respective standards for economic evaluation are best 
seen as pseudoscience in their advocacy of quality adjusted life 
year (QALY) models to inform decision makers; they have more 
in common with intelligent design than natural selection 11 12 
13. 
 
Rather than a commitment to claims for competing products 
that can be assessed through well-designed clinical trials or 
systematic observational studies, the view, as stated in the 
draft for the latest Canadian guidelines is that:   Economic 
evaluations are designed to inform decisions. As such, they are 
distinct from conventional research activities, which are 
designed to test hypotheses. Unfortunately, as pointed out on 
a number of occasions in previous commentaries, building 
simulations to ‘inform decisions’ is hardly an acceptable basis 
for formulary decision making as we have no idea whether the 
constructed claims are right or even whether they are wrong. 
Indeed, the lifetime framework advocated for the decision 
framework, means we will never know. The claims are immune 
to failure. Simulations can be engineered to generate the 
required cost-per-QALY claims. Setting up a reference case to 
mandate simulation parameters does not mean that there is 
not scope to create competing imaginary worlds with 
conflicting, yet unevaluable, be claims. One result of which is 
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that when competing simulations are presented by 
manufacturers to formulary committees, simulated claims 
which more often than not as an integral part of a marketing 
plan support the manufacturer’s product, there is no standard 
for judging the merits of one claim versus another other than 
through a comparison of the various model structures and 
their assumptions14 15 16 17 18. Discriminating through 
hypothesis testing is put to one side. 
 
The HAS Guidelines 
Under the 2012 law for the Financing of Social security, as 
described by de Pouvourville, HAS is required to consider cost-
effectiveness when new drugs and devices are being assessed. 
HAS is then required to make recommendations for access to 
reimbursement together with an assessment of relative value 
versus comparators. Criteria employed are: relative efficacy, 
safety and form of administration. This establishes the relative 
therapeutic index (ITR) for the drug as a guide to pricing. HAS 
does not make final determinations. This is the responsibility 
of the Economic Committee for Health Projects (CEPS). A cost-
effectiveness analysis is complementary to a reimbursement 
decision. Under the decree of October 2012 the elements that 
should be included in the dossier include product efficacy, 
quality, safety, cost, public health benefits, quality of life, 
access to care and ethical compliance.  
 
The HAS guidelines are very much in line with the standards 
found in guidelines that follow the NICE reference case 
paradigm. The focus is on utilizing a decision model framework 
to construct an imaginary world, a reference case that utilizes 
either cost-utility or, where quality of life is not an important 
consideration, cost-effectiveness analysis. The reference case 
has two levels of recommendations: required and preferred.  
The required default timeframe is one that is long enough to 
reflect all expected differences in costs and health effects. In 
practical terms, for chronic disease, the lifetime of the 
modeled cohort. Required outcomes are quality adjusted life 
years (QALYs) for cost-utility analysis and life years in cost-
effectiveness models as preferred outcomes. The required 
outcome criteria for the reference case are an efficiency 
frontier and the calculation of an incremental cost-
effectiveness ratio for non-dominated interventions. The 
detail of the guidelines is covered in 20 recommendations that 
cover the type of economic evaluation, perspective, target 
population, comparators, time horizon, comparators, 
discounting, data sources, outcome measures, costs, choice of 
model, uncertainty and presentation of results.  
 
As detailed by Massetti et al, there are a number of similarities 
between the standards mandated by HAS in the reference case 
and those mandated by NICE. The key similarities are in the 
preference for a cost-utility analysis to define the outcomes of 
competing interventions, the identification of subpopulations, 
the specification of comparators, the default lifetime horizon 
for decision modeling, the focus on effectiveness rather than 
efficacy and the application of sensitivity analysis to capture 
uncertainty in the decision model. The major differences are 
the option, if it can be justified, for cost-effectiveness analysis 
where outcomes are expressed in incremental costs per life 
year gained, defining the target population, the absence of an 
absolute threshold for deciding on the technology’s 
acceptability, methods for the valuation of quality of life and 
the place of the recommendation in the decision process. The 
last point is worth noting. Under NICE the economic evaluation 
is seen to have a major influence in the decision as to whether 
or not a technology should be employed with the limited 
budget of the National Health Service (NHS) while in France the 
technology appraisals are seen as supplementing, along with 
budget impact assessments, pricing negotiations between the 
manufacturer and CEPS.  
 
While these differences between the standards mandated by 
HAS and NICE are of interest, particularly in the context of the 
French model for pricing negotiations, the fact remains that 
both HAS and NICE are asking manufacturers to construct 
imaginary worlds. There is no requirement in either guideline 
that the manufacturer should produce claims that are credible, 
evaluable and replicable. All the health technology assessment 
is required to do is to ‘inform’ the respective decision makers. 
Presumably, if the reference case standards are met then, 
apart from the possibility that an external review group may 
be asked in the French case to evaluate a manufacturer’s 
model, as required by NICE, the acceptance or otherwise of the 
model rests on the assessors’ belief that the model has a 
sufficient correspondence to some ‘reality’. If the 
correspondence is judged sufficient then, as an input to 
formulary and pricing decisions, the claims are necessarily 
accepted.     
 
Discussion 
While not explicitly stated, it is clear that it is not the purpose 
of the HAS guidelines for product claims to be presented that 
are evaluable through either hypothesis testing or systematic 
observation. This is quite clear from the adoption of the 
reference case. A lifetime or long-term perspective in 
modeling and the specification of an efficiency frontier with 
incremental cost-outcomes claims ensures that any claims 
made are immune to failure. Accepting this position puts to 
one side any notion of progress in evaluating the impact of 
competing health technologies in target populations. There is 
a complete lack of feedback on product performance to health 
care decision makers. Most importantly, apart from 
requirements to report on product safety, manufacturers can 
step back, agree to a negotiated price, and feel comfortable 
that the modeled claims can never be scrutinized.  
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Even if we are prepared to accept the NICE reference case 
paradigm, as the majority of health care systems seem 
prepared to do, the mandated standards are still deficient. In 
previous commentaries in this series it was noted that two 
issues appear to be ignored in the reference case standards. 
These are a failure to accommodate: (i) anticipated patterns of 
product adherence and persistence and (ii) potential future 
increases in the price of the product. The obvious question in 
respect of adherence and persistence is why, when the 
majority of patients discontinue their therapy within two to 
three years of the index prescription (and with many exhibiting 
a sub-clinical adherence prior to discontinuation) the 
reference case mandates a default lifetime perspective for the 
decision model? There is a substantial literature on the 
determinants of product discontinuation, pointing to the 
patient’s perception of lack of effectiveness, side effects, cost 
and the entry of new products. Unfortunately, this is put to 
one side in focusing on the technical challenges of building 
lifetime decision models. In common with the NICE reference 
case the HAS model puts anticipated compliance behavior to 
one side. 
 
A further issue, which has been touched upon in previous 
commentaries, is the currency of a simulated or modeled 
claim. Presenting competing claims in the framework of a 
lifetime reference case cost-per-QALY model raises the 
question of how to accommodate potential price increases for 
drug products and devices if the exercise is to generate claims 
that ‘meet’, for example, lifetime willingness-to-pay cost-per-
QALY thresholds. In the US, for example, models developed by 
the Institute for Clinical and Economic Review (ICER) exclude 
any attempt to factor in possible long-term price increases 19. 
Even if the NICE lifetime reference case paradigm is accepted 
by decision makers, the absence of modeling potential price 
increases restricts the currency of any argument that the 
product meets willingness-to-pay thresholds. It flies in the face 
of abundant evidence that, even with clams for moderation in 
price increases and, in the US in particular, policies to offer 
discounts or free access to offset co-payments, manufacturers 
are committed to a policy of systematic price increases over 
the patent life of a product 20 . These increases, semi-annual 
and annual, are all too often in double digits which means that 
within five or six years the product price, putting to one side 
possible discounting arrangements, is doubled. If the potential 
for price increases are not mandated as a reference, case 
standards then any efficiency frontiers and claims for 
incremental cost effectiveness have little relevance beyond 
the immediate timeframe. 
 
Rather than focusing on the construction of imaginary worlds 
to justify product pricing, possible premium prices and 
formulary listing, the solution proposed here is to focus on 
short term models; models than can generate claims that are 
credible, evaluable and replicable, and as a result, provide 
feedback to decision makers in a meaningful time frame. In 
order to illustrate how this could be implemented, the 
Program in Social and Administrative Pharmacy at the 
University of Minnesota, has published a set of proposed 
guidelines for formulary committees 21. These set standards 
for modeled claims, either as extrapolations from clinical trials 
or as stand-alone models, which can be evaluated within a 
two-year time frame. The key requirement is that submissions 
for new products should be accompanied by a protocol 
detailing how the claims are to be evaluated and reported to a 
formulary committee. It is the responsibility of the 
manufacturer to underwrite the study design or to report on 
the results of a parallel study that may have been undertaken 
as part of another submission. There is no restriction on the 
type of claim as long as it is evaluable and is acceptable to the 
formulary committee. The claim can be expressed in utility as 
well as clinical effectiveness terms. Unless the timeframe for 
disease survival is short (e.g., in metastatic cancer 
interventions) claims expressed in cost-per-QALY or cost-per-
life year saved would not be considered credible. Even so, 
there are further questions as to the relevance of QALY 
measures with observed and calculated utility values varying 
significantly, together with concerns over preference 
consistency and the choice of QALY measure 22. There are, in 
fact, instances of short-term models that have been published 
over the last few years 23 24. These short term models which in 
these instances, consider the effectiveness of biologic 
treatments in rheumatoid arthritis in a Spanish target 
population and percutaneous coronary interventions in a 
French target population demonstrate the ease of 
constructing short-term models with evaluable claims.  
 
Redrafting The HAS Guidelines 
It was pointed out in a review of the recently released version 
5 of the Australian PBAC guidelines that abandoning a 
reference case standard does not require a complete rewriting 
of the guidelines. Standards required for comparative clinical 
claims can remain unchanged but with the proviso that their 
re-assessment should be an integral part of the protocol 
assessment. This reflects concerns expressed over the last 
fifteen or more years on the difficulty of reproducing phase 2 
and phase 3 clinical trial claims 25. All too often claims from a 
limited evidence base are taken at face value, either to support 
value propositions for product superiority or as input to 
modeled claims for cost-effectiveness. Requiring 
manufacturers to underwrite a claims assessment protocol 
would go a long way to alleviating concerns as to the veracity 
of clinical claims in target populations and subpopulations. 
 
The single most important modification of the HAS guideline 
would be to require claims to be evaluated and, if necessary, 
replicated in target populations within a 2-year timeframe. 
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This would ensure that manufacturers presented credible 
claims. At the same time the guidelines could follow of 
Minnesota standard and require manufacturers to submit a 
claims assessment protocol. A commitment by a manufacturer 
to underwrite a protocol as a condition for their product to be 
reviewed for formulary listing and pricing is also important 
given the number of instances in which authors of national 
guidelines have pointed to the difficulty of populating 
reference models with ‘national’ data. The HAS guidelines are 
no exception. More generally, France does not possess the 
wealth of administrative claims and linked patient and hospital 
records that in found in the US and which facilitate low cost 
observational studies. This puts a premium on study protocols, 
funded by manufacturers, to evaluate both clinical and cost-
effectiveness claims in French target populations to justify 
modeled claims and to support market entry price 
negotiations and prospective price increases. 
Conclusions 
If claims made for the comparative performance of drugs and 
devices are to meet the standards of normal science, then 
France needs to reject what has been described as the NICE 
paradigm and redraft the HAS guidelines. Modeled claims can 
still inform decision makers but in the context, not of an 
imaginary world with claims driven by constructed evidence, 
but one where there is a commitment by all parties to support 
a progressive research strategy. The focus of the strategy 
should be to report and monitor the health benefits of 
pharmaceuticals in target patient populations. Mandating 
claims evaluation can encompass not only initial product 
listing, where pricing and listing can be considered provisional, 
until manufacturers report on the outcomes of the claim 
evaluation, but also ongoing disease area and therapeutic class 
reviews. Deciding on whether or not a technology is efficient, 
as the basis for a pricing decision, seems pointless when the 
claims presented are non-evaluable. After all, in contributing 
to the invention of science, Descartes in the Discourse on 
Method (1637) played a seminal role in recognizing the 
importance of proposing explanations that could be tested 
experimentally 26.  
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